PBPK models in risk assessment-A focus on chloroprene

Chemico-Biological Interactions

Volumn 166, Issue 1-3, 2007, Pages 352-359

  DeWoskin, Robert S ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Chloroprene; IRIS; PBPK model; Risk assessment; Toxicokinetic

Indexed keywords

CHLOROPRENE;

ARTICLE; COMPUTER MODEL; DOSE RESPONSE; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; HUMAN; RISK ASSESSMENT; TOXICOKINETICS;

ANIMALS; BUTADIENES; CHLOROPRENE; HUMANS; MODELS, BIOLOGICAL; RISK ASSESSMENT;

ANIMALIA; CRICETINAE; MUS; RATTUS; RODENTIA;

EID: 33947133630     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2007.01.016     Document Type: Article

References (19)

1. Keen R.E., and Spain J.D. Computer Simulation in Biology (1992), Wiley-Liss, Inc., New York, USA p. 7
2. US EPA, Glossary of Integrated Risk Information System (IRIS) Terms, Available at: http://www.epa.gov/iris/gloss8.htm#b.
3. DeWoskin R.S., Barone Jr. S., Clewell H.J., and Setzer R.W. Improving the development and use of biologically based dose response models (BBDR) in risk assessment. Hum. Ecol. Risk Assess. 7 5 (2001) 1091-1120
4. U.S. Environmental Protection Agency. Approaches for the Application of Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment, EPA/600/R-05/043F (2006), U.S. Environmental Protection Agency, Washington, DC. http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm%3Fdeid=135427 Available at: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=135427
5. Clark L.H., Setzer R.W., and Barton H.A. Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment. Risk Anal. 24 6 (2004) 1697-1717
6. US EPA, Integrated Risk Information System (IRIS) Home Page, Available at: http://www.epa.gov/iris/index.html.
7. US EPA. International Workshop on Uncertainty and Variability in Physiologically Based Pharmacokinetic (PBPK) Models. Research Triangle Park, NC, USA, October 31-November 2 (2006). http://www.epa.gov/comptox/uvpkm/ Proceedings and white papers available at: http://www.epa.gov/comptox/uvpkm/
8. R.S. DeWoskin, J.C. Lipscomb, C. Thompson, W. Chiu, P. Schlosser, C. Smallwood, J. Swartout, L. Teuschler, A. Marcus, in: J.C. Lipscomb, E.V. Ohanian (Eds.), Pharmacokinetic/Physiologically Based Pharmacokinetic Models in Integrated Risk Information System Assessments, Chapter 15 in Toxicokinetics and Risk Assessment, CRC Press, ISBN: 0849337224, 2006.
9. US Environmental Protection Agency. Health and Environmental Effects Profile for 2-Chloro-1,3-Butadiene, EPA/600/x-84/112 (1984), Environmental Criteria and Assessment Office, Office of Health and Environmental Assessment, Office of Research and Development, Cincinnati, OH
10. US Environmental Protection Agency. Health and Environmental Effects Document for 2-Chloro-1,3-Butadiene (Chloroprene), ECAO-CIN-G037 (1989), Environmental Criteria and Assessment Office, Office of Health and Environmental Assessment, Office of Research and Development, Cincinnati, OH
11. Himmelstein M.W., Gladnick N.L., Donner E.M., Snyder R.D., and Valentine R. In vitro genotoxicity testing of (1-chloroethenyl)oxirane, a metabolite of beta-chloroprene. Chem. Biol. Interact. 135/136 (2001) 703-713
12. Pagan I. Chloroprene: overview of studies under consideration for the development of an IRIS Assessment. IISRP Symposium on Evaluation of Butadiene & Chloroprene Health Effects. September 21 (2005) TBD-reference in this proceedings issue of Chemical-Biological Interactions
13. Himmelstein M.W., Carpenter S.C., and Hinderliter P.M. Kinetic modeling of beta-chloroprene metabolism. I. In vitro rates in liver and lung tissue fractions from mice, rats, hamsters, and humans. Toxicol. Sci. 79 1 (2004) 18-27
14. Himmelstein M.W., Carpenter S.C., Evans M.V., Hinderliter P.M., and Kenyon E.M. Kinetic modeling of beta-chloroprene metabolism. II. The application of physiologically based modeling for cancer dose response analysis. Toxicol. Sci. 79 1 (2004) 28-37
15. Ramsey J.C., and Andersen M.E. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 73 (1984) 159-175
16. Himmelstein M.W., Leonard R., and Valentine R. Kinetic modeling of β-chloroprene metabolism: default and physiologically-based modeling approaches for cancer dose response. IISRP Symposium on Evaluation of Butadiene & Chloroprene Health Effects. September 21 (2005) TBD-reference in this proceedings issue of Chemical-Biological Interactions
17. Cottrell L., Golding B.T., Munter T., and Watson W.P. In vitro metabolism of chloroprene: species differences, epoxide stereochemistry and a de-chlorination pathway. Chem. Res. Toxicol. 14 11 (2001) 1552-1562
18. T. Munter, L. Cottrell, R. Ghai, B.T. Golding, W.P. Watson, The metabolism and molecular toxicology of chloroprene, Chem. Biol. Interact. (2006) (Epub ahead of print).
19. U.S. Environmental Protection Agency. Toxicological Review of Vinyl Chloride, EPA 635/R-00/004 (2000), U.S. Environmental Protection Agency, Washington, DC. http://www.epa.gov/iris/toxreviews/1001-tr.pdf Available online at: http://www.epa.gov/iris/toxreviews/1001-tr.pdf